Research Analysts Issue Forecasts for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Research analysts at HC Wainwright upped their Q1 2025 earnings estimates for Protara Therapeutics in a note issued to investors on Thursday, March 6th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.53) per share for the quarter, up from their prior estimate of ($0.57). HC Wainwright currently has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.74) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($1.75) EPS.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

Several other equities research analysts have also recently commented on the stock. Lifesci Capital started coverage on shares of Protara Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $22.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $4.10 on Monday. Protara Therapeutics has a one year low of $1.60 and a one year high of $10.48. The company has a 50 day moving average of $4.51 and a 200-day moving average of $3.45. The stock has a market cap of $84.58 million, a price-to-earnings ratio of -1.45 and a beta of 1.69.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Protara Therapeutics during the third quarter valued at approximately $60,000. HBK Investments L P acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $106,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $110,000. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $111,000. Finally, Bailard Inc. acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $157,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.